Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: Observation in serial gadoxetic acid-enhanced mri

American Journal of Roentgenology

Volumn 200, Issue 6, 2013, Pages 1254-1260

  Yamamoto, Akira ^a   Ito, Katsuyoshi ^a   Tamada, Tsutomu ^a   Higaki, Atsushi ^a   Kanki, Akihiko ^a   Sato, Tomohiro ^a   Tanimoto, Daigo ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Chronic liver disease; Gadoxetic acid; Hepatocellular carcinoma; Newly developed

Indexed keywords

GADOXETIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HYPERVASCULAR HEPATOCELLULAR CARCINOMA; IMAGE ANALYSIS; IMAGE QUALITY; LIVER CELL CARCINOMA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME; FOLLOW UP; LIVER DISEASE; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PRECANCER; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

MLCS; MLOWN;

EID: 84880935060     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9136     Document Type: Article

References (17)

1. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22:233-237
2. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOBDTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64
3. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31:356-364
4. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009; 19(suppl 5):S975-S989
5. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34:69-78
6. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011; 21:1233-1242
7. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011; 34:88-94
8. Kobayashi S, Matsui O, Gabata T, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 2011; 35:181-186
9. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR 2011; 197:58-63
10. Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Hosoda Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989; 13:1064-1067
11. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22:172-178
12. Eguchi A, Furuta T, Haraguchi M, Matsumata T, Sugimachi K. Multistep, multicentric, and simultaneous development of hepatocellular carcinoma. Am J Gastroenterol 1993; 88:1770-1772
13. Brady CW, Smith AD, Stechuchak KM, et al. Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transpl 2008; 14:228-234
14. Morita K, Taketomi A, Soejima Y, et al. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl 2009; 15: 1412-1416
15. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338
16. Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010; 24:643-650
17. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022